HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (NCT04904588)

🧪 Interventions in This Study

• Busulfan (DRUG)
• Busulfan (DRUG)
• Fludarabine (DRUG)
• Cyclophosphamide (DRUG)
• Melphalan (DRUG)
• Post-transplant Cyclophosphamide (DRUG)
• Mesna (DRUG)
• Tacrolimus (DRUG)
• Mycophenolate Mofetil (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (39 Sites)

Showing the first 25 of 39 sites.

• City of Hope National Medical Center — Duarte, California
• University of California San Francisco — San Francisco, California
• Stanford University — Stanford, California
• Colorado Blood Cancer Institute — Denver, Colorado
• University of Florida Health Shands Hospital — Gainesville, Florida
• University of Miami Sylvester Cancer Center — Miami, Florida
• H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
• Children's Healthcare of Atlanta — Atlanta, Georgia
• Emory University Medical Center — Atlanta, Georgia
• Northwestern University — Chicago, Illinois
• The University of Chicago — Chicago, Illinois
• University of Maryland Medical Center — Baltimore, Maryland
• The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
• Tufts Medical Center — Boston, Massachusetts
• Dana Farber Cancer Institute — Boston, Massachusetts
• University of Michigan Medical Center - Mott Children's Hospita — Ann Arbor, Michigan
• Karmanos Cancer Institute — Detroit, Michigan
• Mayo Clinic Rochester — Rochester, Minnesota
• Washington University/Barnes Jewish Hospital — St Louis, Missouri
• Roswell Park Comprehensive Cancer Center — Buffalo, New York
• Columbia University Medical Center — New York, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• University of North Carolina Chapel Hill — Chapel Hill, North Carolina
• Cincinnati Children's Hospital — Cincinnati, Ohio
• Ohio State Medical Center, James Cancer Center — Columbus, Ohio

📞 Contact the Study Coordinator

Phone: (800) 826-4673

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Acute Lymphoblastic Leukemia

• Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia — Birmingham, Alabama
• Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia — Birmingham, Alabama
• Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia — Duarte, California
• Transcranial Direct Current Stimulation of the Temporal Cortex in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL) — Memphis, Tennessee
• Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy — Duarte, California
• Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease — Houston, Texas

Explore by condition: All Acute Lymphoblastic Leukemia clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.